CBDepot Group starts the marketing of synthesized pharma-grade CBD produced under the EU GMP umbrella of its sister company CB21 Pharma, s.r.o.

During the CPhI 2017 event in Frankfurt, CBDepot introduced, as the first company in the EU, isolated GMP CBD via a third-party contract manufacturer from Prague. Since mid-2019, the group took on a project of relocation of API Cannabidiol manufacture to new premises of CB21 Pharma in Brno.

“This allows CB21 Pharma to bring to the pharmaceutical markets both synthesized and isolated Cannabidiol APIs through exclusive distribution and brokerage arrangements with CBDepot,” says CB21 Pharma CEO Dr Jan Storch.

The now-launched synthesized pharma-grade CBD is compliant with the German DAC monograph.

“This addition will serve the GMP needs in applications or jurisdictions where the use of plant-based Cannabidiol API is not possible,” concludes Boris Baňas, CBDepot’s Chief Sales Officer.